Featured Publications
Auditory feature perception and auditory hallucinatory experiences in schizophrenia spectrum disorder
Schnakenberg Martin AM, Bartolomeo L, Howell J, Hetrick WP, Bolbecker AR, Breier A, Kidd G, O’Donnell B. Auditory feature perception and auditory hallucinatory experiences in schizophrenia spectrum disorder. European Archives Of Psychiatry And Clinical Neuroscience 2017, 268: 653-661. PMID: 28936548, PMCID: PMC7126185, DOI: 10.1007/s00406-017-0839-1.Peer-Reviewed Original ResearchConceptsAuditory verbal hallucinationsSchizophrenia spectrum disordersAuditory perceptionSZ individualsFeature perceptionVerbal hallucinationsSpectrum disorderAuditory featuresImpaired auditory perceptionSchizophrenia Voices QuestionnaireBasic Auditory CapabilitiesTemporal order discriminationAuditory hallucinatory experiencesCognitive processingTone taskOrder discriminationHamilton ProgramHallucinatory experiencesGreater deficitsSZ groupAuditory hallucinationsAuditory capabilitiesPerceptionVoice QuestionnaireIntellectual impairment
2021
Altered cerebellar-cortical resting-state functional connectivity in cannabis users
Martin A, Kim DJ, Newman SD, Cheng H, Hetrick WP, Mackie K, O’Donnell B. Altered cerebellar-cortical resting-state functional connectivity in cannabis users. Journal Of Psychopharmacology 2021, 35: 823-832. PMID: 34034553, PMCID: PMC8813046, DOI: 10.1177/02698811211019291.Peer-Reviewed Original ResearchConceptsResting-state functional connectivityNon-using peersCannabis usersCannabis useFunctional connectivityRegular cannabis usersPosterior cingulate cortexAnterior cerebellar regionsNon-motor phenomenaCingulate cortexCerebellar regionsBrain regionsAge of initiationCerebral regionsCerebellar lobulesCortexPeersLifetime useUnbiased atlas templateIndividual voxelsCerebral cortexReceptor densityCognitionCerebellumAtlas template
2020
In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers
Schindler EAD, Schnakenberg Martin AM, Sewell RA, Ranganathan M, DeForest A, Pittman BP, Perrino A, D’Souza D. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. Psychopharmacology 2020, 237: 3097-3107. PMID: 32632491, DOI: 10.1007/s00213-020-05595-9.Peer-Reviewed Original ResearchConceptsCapsaicin-induced hyperalgesiaCross-over studyHealthy human subjectsIntravenous THCAcute painAntinociceptive effectDrug effectsDrug AdministrationHuman subjectsDose-related mannerPeak drug effectHealthy human volunteersSignificant antinociceptive propertiesRationaleAnimal studiesElectrical painPain conditionsPain managementChemical painPain ratingsAntinociceptive propertiesHealthy volunteersPsychoactive dosesAcute chemicalHuman studiesCognitive alterations
2019
Individuals with psychosis and a lifetime history of cannabis use show greater deficits in emotional experience compared to non-using peers
Martin A, Lysaker PH. Individuals with psychosis and a lifetime history of cannabis use show greater deficits in emotional experience compared to non-using peers. Journal Of Mental Health 2019, 29: 77-83. PMID: 30822177, DOI: 10.1080/09638237.2018.1487540.Peer-Reviewed Original ResearchConceptsEmotional Expressivity ScaleEmotional experienceSocial Functioning ScaleEmotional expressionAnticipatory pleasureLifetime cannabisSocial functioningGreater deficitsSocial functionCannabis useNon-using peersAnticipation of pleasureExperience of pleasurePoor social functionEmotional expressivityLifetime historyAnticipatory anhedoniaProsocial activitiesActive cannabisPleasure ScaleTemporal experienceHistory of cannabisFunctioning ScaleEarly psychosisPrevious research
2018
Aberrant structural–functional coupling in adult cannabis users
Kim D, Martin A, Shin Y, Jo HJ, Cheng H, Newman SD, Sporns O, Hetrick WP, Calkins E, O'Donnell BF. Aberrant structural–functional coupling in adult cannabis users. Human Brain Mapping 2018, 40: 252-261. PMID: 30203892, PMCID: PMC6289814, DOI: 10.1002/hbm.24369.Peer-Reviewed Original ResearchConceptsStructural-functional couplingSC-FC couplingResting-state functional imagingCB usersPrimary outcome measureCannabis usersCB1 receptor densityRegion-specific disruptionCB useChronic cannabis useFunctional brain connectivityRich-club organizationOutcome measuresReceptor densitySynaptic plasticityRich-club analysisCannabis useFunctional connectivityBrain connectivityFunctional imagingAdult cannabis usersFunctional couplingBrain networksPositive associationHippocampusThe effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D’Souza D, Ranganathan M. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 2018, 235: 1923-1932. PMID: 29619533, DOI: 10.1007/s00213-018-4885-9.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAffectAntipsychotic AgentsCannabidiolChronic DiseaseCognitionCognitive DysfunctionDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMental Status and Dementia TestsMiddle AgedOutpatientsPsychiatric Status Rating ScalesSchizophreniaSchizophrenic PsychologyTreatment OutcomeConceptsMATRICS Consensus Cognitive BatterySide effectsChronic schizophreniaAntipsychotic-treated patientsMovement side effectsFixed-dose studyPlacebo-treated subjectsWeeks of treatmentPANSS total scoreEffects of cannabidiolWorsening of moodNegative Syndrome ScaleAntipsychotic-treated outpatients× time effect× time interactionMCCB composite scoreOral cannabidiolCBD groupClinical trialsParallel groupPANSS scoresMethodsThis studyPsychotic symptomsConsensus Cognitive BatterySyndrome Scale
2017
Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information
Ranganathan M, Radhakrishnan R, Addy PH, Schnakenberg-Martin AM, Williams AH, Carbuto M, Elander J, Pittman B, Sewell R, Skosnik PD, D'Souza DC. Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2017, 79: 176-183. PMID: 28642081, DOI: 10.1016/j.pnpbp.2017.06.019.Peer-Reviewed Original ResearchConceptsRey Auditory Verbal Learning TestVerbal informationInfluence of tetrahydrocannabinolVerbal Learning TestMemory-impairing effectsTotal immediate recallNon-verbal informationImpairs memory consolidationAdministration of tetrahydrocannabinolAcute memory impairmentPrincipal psychoactive constituentVerbal memoryImmediate recallIntravenous tetrahydrocannabinolLearning TestMemory consolidationComponent processesNeural synchronyMemory impairmentInformation processingUse of cannabisCannabis intoxicationRecallPsychoactive constituentEncodingThe positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition
Helle S, Løberg EM, Gjestad R, Martin A, Lysaker PH. The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. Psychiatry Research 2017, 250: 92-98. PMID: 28152399, DOI: 10.1016/j.psychres.2017.01.047.Peer-Reviewed Original ResearchConceptsSocial cognitionTheory of mindExecutive functionCannabis useBell-Lysaker Emotion Recognition TestEmotion Recognition TestExecutive Functioning ScaleBetter executive functionRegular cannabis useStructural equation modelingHinting testIllicit substancesNeurocognitive vulnerabilityRecognition testNeurocognitive performanceNeurocognitive deficitsCognitionEquation modelingFlexibility componentsAlcohol useFunctioning ScaleLifetime cannabisIndirect effectsPositive linkSchizophrenia
2015
GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC
Radhakrishnan R, Skosnik PD, Cortes-Briones J, Sewell RA, Carbuto M, Schnakenberg A, Cahill J, Bois F, Gunduz-Bruce H, Pittman B, Ranganathan M, D'Souza DC. GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC. Neuropsychopharmacology 2015, 40: 2047-2056. PMID: 25728472, PMCID: PMC4839528, DOI: 10.1038/npp.2015.58.Peer-Reviewed Original Research
2012
Acute effects of THC on time perception in frequent and infrequent cannabis users
Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D’Souza D. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology 2012, 226: 401-413. PMID: 23179965, PMCID: PMC3581701, DOI: 10.1007/s00213-012-2915-6.Peer-Reviewed Original ResearchConceptsCannabis smokersAcute effectsFrequent cannabis smokersPlacebo-controlled studyCannabis usersChronic cannabis smokersInfrequent cannabis usersWhole-plant cannabisChronic cannabis useResultsAll dosesVariable pharmacokineticsBlunted responseSubjects three timesHigh dosesTHC effectsFrequent cannabis usersCannabis useInternal clock speedΔ9-tetrahydrocannabinolSmall sample sizeDosesFrequent cannabisThree timesTest daySmokersDose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans
Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D'Souza DC. Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans. Biological Psychiatry 2012, 72: 871-879. PMID: 22817868, PMCID: PMC3638802, DOI: 10.1016/j.biopsych.2012.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAdultCardiovascular SystemCognitionCross-Over StudiesDiterpenes, ClerodaneDose-Response Relationship, DrugDrug MonitoringElectroencephalographyEuphoriaFemaleHallucinogensHumansHydrocortisoneIllicit DrugsMalePerceptionProlactinPsychiatric Status Rating ScalesPsychoses, Substance-InducedReceptors, Opioid, kappaSensationConceptsSA administrationSalvinorin APopular recreational drugElectroencephalogram spectral powerPrimary active ingredientPsychotomimetic effectsReceptor agonismOpiate receptorsEndocrine effectsHealthy subjectsSelective agonistHealthy individualsPerceptual alterationsPlasma cortisolEuphoric effectsCognitive deficitsRecreational drugsVital signsCounterbalanced studyEffect of SAYoung adultsAdverse effectsPsychophysiological effectsIndividual variabilityAdministrationDose-Related Modulation of Event-Related Potentials to Novel and Target Stimuli by Intravenous Δ9-THC in Humans
D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, Carbuto M, Elander J, Schnakenberg A, Pittman B, Sewell RA, Ranganathan M, Mathalon D. Dose-Related Modulation of Event-Related Potentials to Novel and Target Stimuli by Intravenous Δ9-THC in Humans. Neuropsychopharmacology 2012, 37: 1632-1646. PMID: 22334121, PMCID: PMC3358754, DOI: 10.1038/npp.2012.8.Peer-Reviewed Original ResearchConceptsRecent cannabis usersPerceptual alterationsERP componentsCannabis usersEvent-related potential taskSensory ERP componentsCannabis Use StatusModulation of eventsΔ9-THCProperties of cannabisContext updatingNeural correlatesP3b amplitudeTarget stimuliPsychophysiological indicesCortical processesP300b amplitudesProcessing speedCognitive deficitsPsychophysiological dataInformation processingAutomatic orientationCounterbalanced designSubjective effectsPotential tasks
2011
The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories
Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D’Souza D, The Yale THC Study Group. The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology 2011, 219: 885-896. PMID: 21845389, DOI: 10.1007/s00213-011-2417-y.Peer-Reviewed Original ResearchConceptsAdverse eventsPost-study periodCareful subject selectionMinor adverse eventsPhysical adverse eventsFrequent side effectsLong-term followCannabinoid receptor systemFaster infusion rateCannabinoid receptor ligandsIntravenous THCPlacebo infusionCannabinoid systemInfusion rateStudy participationSide effectsAbuse liabilityHigh dosesReceptor systemΔ9-tetrahydrocannabinolInfusionPsychoactive effectsReceptor ligandsTest daySubjects